BioPharmSignal logoBioPharmSignal

Biotech News

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals (RCKT)Rocket PharmaceuticalsEarnings

Pivotal Phase 2 trial of RP-A501 for Danon disease progressing with dosing reinitiated First patient dosing in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in mid-2026 KRESLADI™ granted FDA accelerated approval; Rare Pediatric Disease Priority Review Voucher

Related news

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

CRNXCrinetics Pharmaceuticals2026-08-03 20:05 EST

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

CRNXCrinetics Pharmaceuticals2026-06-30 20:05 EST

Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

SRPTSarepta Therapeutics2026-08-05 20:05 EST

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

NTLAIntellia2026-08-06 11:00 EST

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

ARWRArrowhead Pharmaceuticals2026-08-04 20:01 EST

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

IRONDisc Medicine2026-07-30 12:30 EST

Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update

RIGLRigel Pharmaceuticals2026-07-28 12:05 EST

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

View all latest news

Rocket Pharmaceuticals

Gene Therapies for Rare Disease Rocket Pharmaceuticals develops gene therapies for rare hematologic and cardiovascular disorders using lentiviral and adeno-associated-virus vectors. Commercial Hematology Franchise KRESLADI is an ex vivo lentiviral gene therapy approved for severe leukocyte adhesion deficiency type I. It represents...

Recent company news

RCKTRocket Pharmaceuticals2026-08-03 11:00 EST

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

RCKTRocket Pharmaceuticals2026-06-12 11:00 EST

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

RCKTRocket Pharmaceuticals2026-05-28 11:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

RCKTRocket Pharmaceuticals2026-05-07 20:00 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

RCKTRocket Pharmaceuticals2026-04-28 11:00 EST

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Stock data

Close
3.54 USD
Market cap
315.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States